Literature DB >> 6798122

Genetic control of the immune response to myoglobins. VI. Distinct Ir genes for different myoglobins: complementing genes in I-A and H-2D for equine myoglobin.

J A Berzofsky, G K Buckenmeyer, G Hicks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6798122

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  6 in total

1.  Experimental allergic orchitis in mice. VI. Recombinations within the H-2S/H-2D interval define the map position of the H-2-associated locus controlling disease susceptibility.

Authors:  C Teuscher; D L Gasser; S R Woodward; W F Hickey
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

2.  A possible immunodominant epitope recognized by murine T lymphocytes immune to different myoglobins.

Authors:  I Berkower; G K Buckenmeyer; F R Gurd; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

3.  Human helper T-cell clones that recognize different influenza hemagglutinin determinants are restricted by different HLA-D region epitopes.

Authors:  D D Eckels; T W Sell; S R Bronson; A H Johnson; R J Hartzman; J R Lamb
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

4.  Influences of antigen processing on the expression of the T cell repertoire. Evidence for MHC-specific hindering structures on the products of processing.

Authors:  S J Brett; K B Cease; J A Berzofsky
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

5.  IR gene regulation of the response to trinitrophenyl-polysaccharides. Two independent genes are required for antibody production.

Authors:  L M Hillstrom; J E Niederhuber
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

6.  Monoclonal antibody characterization of a unique immune response control locus between H-2S and D.

Authors:  L H Shapiro; E S Dugan; J E Neiderhuber
Journal:  J Exp Med       Date:  1985-11-01       Impact factor: 14.307
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.